O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

Michel Ducreux, Ghassan K. Abou‐Alfa, Zhenggang Ren, Julien Edeline, Z. Li, Eric Assénat, Lorenza Rimassa, J.F. Blanc, Paul J. Ross, Weijia Fang, Sheng Hu, T. Zhang, Albert Tran, Hongming Pan, Chia‐Jui Yen, J. Wu, V. Li, Sandra Chica-Duque, Philippe Merle, Ann‐Lii Cheng